FungaBeam releases an informational overview outlining how its nail fungus light device is described in company materials, including technology context, usage expectations, and safety considerations ...

The US FDA has accepted Sun Pharmaceutical's supplemental Biologics License Application (sBLA) for ILUMYA, a treatment for ...

The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has ...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US ...

Sun Pharmaceutical Industries Limited has announced that the US Food and Drug Administration (USFDA) has accepted for review its supplemental Biologics License Application (sBLA) ...

US FDA accepts Sun Pharma’s sBLA for Ilumya to treat adults with active psoriatic arthritis: Our Bureau, Mumbai Tuesday, March 17, 2026, 10:30 Hrs [IST] Sun Pharmaceutical Indus ...

Sun Pharmaceutical Industries Limited. Sun Pharma announces US FDA acceptance of supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active ...

Ilumya has secured marketing authorisations from more than 55 health authorities worldwide.

Sun Pharmaceutical Industries said that the US Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab) for the ...

If the sBLA is approved, expansion into psoriatic arthritis would build on the established clinical experience of ILUMYA as an IL-23 inhibitor for moderate-to-severe ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...

Hidradenitis suppurativa is a skin disease that causes outbreaks of bumps and abscesses. It's thought to affect around 1% of ...